Q1 2026 saw improved financials with narrowed losses and a significant scientific milestone as Temodex demonstrated a 5.6-month survival benefit. Strategic focus is on licensing, portfolio control, and leveraging new clinical data for commercial growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.